Congresses

Title Yearsort descending
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria 2020
Development Of An Efficient In Vitro High-Throughput Method To Discover New Combinatorial Therapies Against Non-Tuberculous Mycobacteria 2020
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Clinical trial design optimisation and dose rationale for the treatment of Buruli ulcer antibiotic combination therapy 2021
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
The veterinary anthelmintic selamectin inhibits the mycobacterial DprE1 enzyme 2022
Repurposing Beta-lactams for Buruli Ulcer Therapy, from the Bench to the Clinic 2022
Recapitulation of pulmonary SARS-CoV-2 infection in vitro in a novel 3D human lung organoid model with innate immune and stromal cells 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022
Study of in vitro and in vivo activity of a novel compound against Mycobacterium abscessus for the treatment of cystic fibrosis infections 2022
A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens 2022
Régimen con betalactámicos para reducir el tratamiento de la úlcera de Buruli: tratamiento estándar de 8 semanas (rifampicina más claritromicina) versus 4 semanas de tratamiento estándar más amoxicilina/clavulanato [RC8 vs. RCA4] (ensayo clínico BLMs4BU) 2022
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative 2022
OPTIKA, a new high content in vitro kill-kinetic assay to evaluate the efficacy of novel anti-TB drug combinations 2022

Pages